XPro1595 Improves Outcomes in a Mouse Model of TBI-induced Alzheimer’s Disease
April 19 2023 - 7:30AM
INmune Bio, Inc. (NASDAQ: INMB) (the
“Company”), a clinical-stage immunology company focused on
developing treatments that harness the patient’s innate immune
system to fight disease, announced pre-clinical data detailing
research led by Kirsty J. Dixon of the Department of Surgery,
Virginia Commonwealth University (VCU), and Elliott Mufson, Barrow
Neurological Institute. In the pre-clinical study, Alzheimer’s
Disease related amyloid pathology increased after Traumatic Brain
Injury (TBI) in an at-risk mouse model. Treatment with XPro™ one
hour after TBI prevents the development of amyloid pathology in the
brain. These data show that soluble TNF drives the development of
amyloid pathology after TBI, which can be prevented by neutralizing
sTNF with XPro™.
“The unfortunate reality of TBI is that the acute injury often
overshadows the long-term consequences, which includes the
potential for later developing Alzheimer’s disease,” said Kirsty
Dixon, Assoc. Prof. of Surgery at VCU. “My team that includes Ph.D.
student Michelle Taylor, and MD/Ph.D. student Chelsie Poffenberger
investigate the role of soluble TNF in both the acute injury
setting and chronically following TBI. We hope this research
may determine the relationship between TBI and AD.”
“TBI remains a major health problem affecting more than 50
million people worldwide per year,” said RJ Tesi MD, CEO of
INmune Bio, “Few realize that the elderly have the greatest
risk of hospitalizations and death due to TBI. The ability of XPro
to prevent amyloid formation after head injury suggests early
intervention may help to prevent the development of AD in the
elderly with TBI.”
The Company provided XPro1595 to Kirsty Dixon and her research
team through an MTA collaboration with VCU. The Company, and its
research partners continue to investigate the involvement of
soluble TNF and potential applications of XPro1595 for treating
disease. The data was presented in a poster at the AD/PD™ 2023
International Conference on Alzheimer’s and Parkinson’s Disease in
Gothenburg, Sweden on 1 April 2023.
About XPro1595
XPro™ is a next-generation inhibitor of tumor necrosis factor
(TNF) that is currently in clinical trials and acts differently
than currently available TNF inhibitors in that it neutralizes
soluble TNF (sTNF), without affecting trans-membrane TNF (tmTNF) or
TNF receptors. XPro™ could potentially have substantial beneficial
effects in patients with neurologic disease by decreasing
neuroinflammation and restoring innate immune cell function. For
more information about the importance of targeting
neuroinflammation in the brain to improve cognitive function and
restore neuronal communication visit this section of the
INmune Bio’s website.
About INmune Bio, Inc.
INmune Bio, Inc. is
a publicly traded (NASDAQ: INMB), clinical-stage biotechnology
company focused on developing treatments that target the innate
immune system to fight disease. INmune Bio has two product
platforms that are both in clinical trials: The Dominant-Negative
Tumor Necrosis Factor (DN-TNF) product platform utilizes
dominant-negative technology to selectively neutralize soluble TNF,
a key driver of innate immune dysfunction and a mechanistic driver
of many diseases. DN-TNF product candidates are in clinical trials
to determine if they can treat cancer (INB03™), Early Alzheimer’s
disease, and treatment-resistant depression (XPro™). The Natural
Killer Cell Priming Platform includes INKmune™ developed to prime a
patient’s NK cells to eliminate minimal residual disease in
patients with cancer. INmune Bio’s product platforms utilize a
precision medicine approach for the treatment of a wide variety of
hematologic and solid tumor malignancies, and chronic inflammation.
To learn more, please
visit www.inmunebio.com.
Forward Looking Statements
Clinical trials are in early stages and there is no assurance
that any specific outcome will be achieved. Any statements
contained in this press release that do not describe historical
facts may constitute forward-looking statements as that term is
defined in the Private Securities Litigation Reform Act of
1995. Any statements contained in this press release that do
not describe historical facts may constitute forward-looking
statements as that term is defined in the Private Securities
Litigation Reform Act of 1995. Any forward-looking statements
contained herein are based on current expectations but are subject
to a number of risks and uncertainties. Actual results and the
timing of certain events and circumstances may differ materially
from those described by the forward-looking statements as a result
of these risks and uncertainties. INB03™, XPro1595 (XPro™), and
INKmune™ are still in clinical trials or preparing to start
clinical trials and have not been approved by the US Food and Drug
Administration (FDA) or any regulatory body and there cannot be any
assurance that they will be approved by the FDA or any regulatory
body or that any specific results will be achieved. The factors
that could cause actual future results to differ materially from
current expectations include, but are not limited to, risks and
uncertainties relating to the Company’s ability to produce more
drug for clinical trials; the availability of substantial
additional funding for the Company to continue its operations and
to conduct research and development, clinical studies and future
product commercialization; and, the Company’s business, research,
product development, regulatory approval, marketing and
distribution plans and strategies. These and other factors are
identified and described in more detail in the Company’s filings
with the Securities and Exchange Commission, including the
Company’s Annual Report on Form 10-K, the Company’s Quarterly
Reports on Form 10-Q and the Company’s Current Reports on Form 8-K.
The Company assumes no obligation to update any forward-looking
statements in order to reflect any event or circumstance that may
arise after the date of this release.
INmune Bio Contact: David
Moss, CFO (858) 964-3720 info@inmunebio.com
Investor Contact: Jason
Nelson Core IR (516) 842-9614 x-823
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From Apr 2024 to May 2024
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From May 2023 to May 2024